Two Sigma Securities LLC Makes New Investment in Galectin Therapeutics Inc. (NASDAQ:GALT)

Two Sigma Securities LLC acquired a new stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 28,571 shares of the company’s stock, valued at approximately $37,000.

A number of other institutional investors also recently modified their holdings of the company. Barclays PLC raised its position in Galectin Therapeutics by 91.1% during the 4th quarter. Barclays PLC now owns 54,634 shares of the company’s stock valued at $71,000 after purchasing an additional 26,047 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Galectin Therapeutics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 870,589 shares of the company’s stock valued at $1,124,000 after acquiring an additional 8,047 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Galectin Therapeutics by 94.9% during the fourth quarter. JPMorgan Chase & Co. now owns 59,693 shares of the company’s stock valued at $77,000 after acquiring an additional 29,065 shares in the last quarter. LPL Financial LLC boosted its holdings in Galectin Therapeutics by 69.6% in the fourth quarter. LPL Financial LLC now owns 138,928 shares of the company’s stock valued at $179,000 after acquiring an additional 57,020 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new position in Galectin Therapeutics during the 4th quarter valued at $29,000. 11.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Galectin Therapeutics in a research report on Wednesday, April 2nd.

Galectin Therapeutics Stock Performance

Shares of NASDAQ:GALT opened at $1.39 on Friday. The firm has a market capitalization of $87.82 million, a P/E ratio of -1.90 and a beta of 0.79. The stock has a 50 day moving average price of $1.45 and a 200-day moving average price of $1.73. Galectin Therapeutics Inc. has a 52-week low of $0.73 and a 52-week high of $3.59.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). On average, equities analysts forecast that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.